Raymond James Financial
HRTX icon

Raymond James Financial’s Heron Therapeutics HRTX Stock Holding History

Raymond James Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$111K Buy
138,203
+18,004
+15% +$20.9K ﹤0.01% 5012
2025
Q4 		$156K Buy
120,199
+8,527
+8% +$10.5K ﹤0.01% 4846
2025
Q3 		$141K Buy
111,672
+450
+0.4% +$713 ﹤0.01% 4691
2025
Q2 		$230K Sell
111,222
-25,000
-18% -$51.1K ﹤0.01% 4443
2025
Q1 		$300K Buy
136,222
+500
+0.4% +$970 ﹤0.01% 4220
2024
Q4 		$208K Buy
+135,722
New +$220K ﹤0.01% 4389

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Raymond James Financial's HRTX Position: Q1 2026 in Review

Raymond James Financial increased its Heron Therapeutics (HRTX) stake by 15% in Q1 2026, buying an estimated $20.9K and bringing the position to 138,203 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #5012.

Raymond James Financial first reported a position in HRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $300K in Q1 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Raymond James Financial held 138,203 shares of Heron Therapeutics worth $111K as of Q1 2026.
  • Raymond James Financial bought 18,004 Heron Therapeutics shares in Q1 2026, an estimated $20.9K.
  • Heron Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5012 holding.
  • Raymond James Financial first reported a position in Heron Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Heron Therapeutics position peaked at $300K in Q1 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.